Default Logo White

The Most Influential People in Psychedelics

An integral part of our mission is to inform and inspire those curious about psychedelics. With that in mind, we celebrate the achievements of those who came before us, those who work alongside us, and those who are poised to bring psychedelics and psychedelic research into the future. While this list will never be truly “complete,” it is meant to reflect the foundational pillars in this space, and important emerging voices. While many people’s achievements would place them in multiple categories, we have attempted to place them in their area of greatest contribution. This list will continue to evolve and grow, and we welcome feedback and discussion. Have we missed someone? Contact us or reach out on Instagram to nominate an expert for inclusion. Browse and click individual submissions below to learn more.

Traditional Practitioners

Belinda-Eriacho
Belinda Eriacho, MPH Founder, KAALOGII

Belinda Eriacho, MPH

Founder, KAALOGII

Belinda Eriacho, who is of Zuni and Dine’ (Navajo) descent and was born and raised on the Dine’ reservation, in Crystal, New Mexico. Eriacho is a speaker, practitioner, healer, wisdom carrier, educator, author, and founder of Kaalogii, where she helps facilitate healing, inner awakening, self-discovery, and transformation. In addition to her degrees in Public Health, Health Sciences, and Technology, she is also trained in the MAPS MDMA-Assisted Therapy program and is currently going through Ketamine-Assisted Therapy training. She is a Native American Traditional Advisor for SoundMind Center for Psychedelic Healing, a treatment facility that provides psychedelic-assisted therapy. Further, she’s a contributing author to the book, Psychedelic Justice: Toward a Diverse and Equitable Psychedelic Culture.

White X
Carlos-Castaneda
Carlos Castaneda, Ph.D. Author, THE TEACHINGS OF DON JUAN: A YAQUI WAY OF KNOWLEDGE

Carlos Castaneda, Ph.D.

Author, THE TEACHINGS OF DON JUAN: A YAQUI WAY OF KNOWLEDGE

Carlos Castaneda was a Peruvian-born anthropologist and the author of many books, including The Teachings of Don Juan: A Yaqui Way of Knowledge, A Separate Reality, and Journey to Ixtlan, which he wrote as an anthropology student at UCLA. These books documented the teachings he received from Yaqui “Man of Knowledge,” Don Juan Matus, including how to use plants like psilocybin, datura, and peyote to gain insight into other states of reality. His books have sold millions of copies worldwide.

White X
Dennis-Banks
Dennis Banks ACTIVIST, TEACHER, CO-FOUNDER, AMERICAN INDIAN MOVEMENT

Dennis Banks

ACTIVIST, TEACHER, CO-FOUNDER, AMERICAN INDIAN MOVEMENT

Dennis Banks, also known as Nowa Cumig, was born on Leech Lake Indian Reservation, and a member of the Turtle Clan. He was a long-time activist, co-founding the American Indian Movement (AIM) in Minneapolis to help protect the rights of urban Indigenous people who experienced systemic oppression, discrimination, and poverty. He founded and led Sacred Run in 2006, with the first run covering 500 miles, from Davis, CA, to Los Angeles, CA. Since then, the Sacred Run has expanded to an annual event held in the United States, Canada, Japan and Europe. Those who participated brought a message of “Land, Life, and Peace” to those they saw along the way. He was also the author of his autobiography, Ojibwa Warrior: Dennis Banks and the Rise of the American Indian Movement.

White X
Elaine-Elisabetsky
Elaine Elisabetsky, Ph.D. PROFESSOR OF PHARMACOLOGY, THE FEDERAL UNIVERSITY OF RIO GRANDE DO SUL

Elaine Elisabetsky, Ph.D.

PROFESSOR OF PHARMACOLOGY, THE FEDERAL UNIVERSITY OF RIO GRANDE DO SUL

Elaine Elisabetsky, a doctor, activist, researcher, and professor, is a member of the WHO Traditional, Complementary and Integrative Medicine advisory panel. She also consults for several private companies and government agencies. Over the course of her career, she has published more than 150 scientific articles and book chapters about the medicinal properties of various plants and isolated compounds, which has contributed to advancing the field of psychedelic-assisted therapy. She is also a founding member of the International Society of Ethnobiology and the International Society of Ethnopharmacology.

White X
James-Mooney
James “Flaming Eagle” Mooney ELDER SEMINOLE MEDICINE MAN EMERITUS, AND CO-FOUNDER, OKLEVUEHA NATIVE AMERICAN CHURCH

James “Flaming Eagle” Mooney

ELDER SEMINOLE MEDICINE MAN EMERITUS, AND CO-FOUNDER, OKLEVUEHA NATIVE AMERICAN CHURCH

James Warren “Flaming Eagle” Mooney is an Elder Medicine Man, or traditional healer, and co-founder of Oklevueha Native American Church. He has fought for the use of marijuana, peyote, and ayahuasca as sacred plants in the church. He also serves on the Salt Lake Interfaith Roundtable, where he represents Indigenous spirituality and cultures. Mooney served as a representative for the Indigenous Peoples of the World at the United Nations, and has been granted several awards, including the Volunteer Service Award, recognized by President Barack Obama, and the Citizens Award of Commendation from Governor Michael Leavitt.

White X
Maria Sabina
Maria Sabina CURANDERA, SAINT MOTHER OF THE SACRED MUSHROOMS, HUAUTLA DE JIMÉNEZ

Maria Sabina

CURANDERA, SAINT MOTHER OF THE SACRED MUSHROOMS, HUAUTLA DE JIMÉNEZ

Maria Sabina was a Mazatec poet and curandero in Oaxaca, Mexico. She held veladas, or healing ceremonies, using psilocybin mushrooms, known as teonanacatl in the Nahuatl language, that were sacred to Mazatec communities. Though this wasn’t her intent, her veladas helped contribute to the popularity of magic mushroom use among people in the United States and Europe, as well as modern medicine. Making her the unofficial mother of the modern psychedelic movement. Sabina was the first contemporary healer to allow American and European travelers to participate in a velada ceremony. One of these was R. Gordon Wasson, who collected fungal spores in Mexico and brought them to Paris, where Albert Hofmann eventually isolated the psychoactive ingredient, psilocybin.

White X
Marlena-Robbins
Marlena Robbins DOCTORAL STUDENT, UC BERKELEY SCHOOL OF PUBLIC HEALTH, CENTER FOR THE SCIENCE OF PSYCHEDELICS FELLOW

Marlena Robbins

DOCTORAL STUDENT, UC BERKELEY SCHOOL OF PUBLIC HEALTH, CENTER FOR THE SCIENCE OF PSYCHEDELICS FELLOW

Marlena Robbins, who is Diné from the Yeii Dine’e Táchii’nii (Giant Red Running into Water) people, has a Master’s in American Indian Studies, Indigenous Rights and Social Justice from ASU. Her studies have focused on art as a means of healing and wellness within the Indigenous community. During her doctoral program at UC Berkeley School of Public Health, she is focusing on protocols of psychedelic-assisted therapy and public education regarding psychedelics, as well as traditional and heritage practices. Robbins is also an Indigenous science fellow at the Berkeley Center for the Science of Psychedelics, where her work will assist in the advancement of psychedelic-assisted therapy from an Indigenous perspective. She also serves as the Indigenous and Community Affairs Officer at the Chacruna Institute.

White X
Quanah-Parker
Quanah Parker LEADER AND PRINCIPAL CHIEF, COMANCHE NATION

Quanah Parker

LEADER AND PRINCIPAL CHIEF, COMANCHE NATION

Quanah Parker, a war leader, and last chief of the Kwahadi band of the Comanche Nation. Parker was eventually appointed as Principal Chief of the Comanche Nation. He was one of the leaders of the Native American Church movement and a key figure in fighting for the legal use of peyote for Indigenous religious practices.

White X
Sandor-Iron-Rope
Sandor Iron Rope BOARD OF DIRECTOR, INDIGENOUS PEYOTE CONSERVATION INITIATIVE

Sandor Iron Rope

BOARD OF DIRECTOR, INDIGENOUS PEYOTE CONSERVATION INITIATIVE

Sandor Iron Rope is the President of the Native American Church of South Dakota, the Executive Director of Tiognaka Tawowaka Otokahe, a Lakota family healing center, and an enrolled member of the Oglala Lakota Oyate. Iron Rope is a peyote practitioner, serving as a Board member of the Indigenous Peyote Conservation Initiative and advocating for its medicinal use in healing and wellness practices.

White X
Sutton-King
Sutton King, MPH CO-FOUNDER AND PRESIDENT, URBAN INDIGENOUS COLLECTIVE

Sutton King, MPH

CO-FOUNDER AND PRESIDENT, URBAN INDIGENOUS COLLECTIVE

Sutton King, a descendant of the Oneida and Menominee Nations of Wisconsin, is a public speaker, activist, and researcher committed to improving Indigenous health equity. She is Co-founder and President of Urban Indigenous Collective, a public health nonprofit that improves Indigenous access to culturally-responsive health services. She is also the Program Manager of Engagement and Benefit Sharing at the Indigenous Medicine Conservation Fund, which is committed to ensuring Indigenous people, who first used the sacred medicines of peyote, psilocybin, and ayahuasca, are respected and uplifted.

White X
Ynes-Sanchez-Gonzales
Ynes Sanchez Gonzales CURANDERA, THE TEMPLE OF THE WAY OF LIGHT

Ynes Sanchez Gonzales

CURANDERA, THE TEMPLE OF THE WAY OF LIGHT

Ynes Sanchez Gonzales has been working with medicinal plants like ayahuasca for over 50 years. She was one of the first Shipibo healers who joined the Temple of the Way of Light, a healing center in the Peruvian Amazon, where she facilitates ayahuasca retreats for guests from all around the world. As a Maestra with the Temple of the Way of Life, Gonzales was instrumental in the development of the plant-based dietas used in the lead up to sacred ayahuasca ceremonies. Gonzales is known for her vision, compassion, and incredible healing ability.

White X

Science

headshot Adam Safron
Adam Safron, Ph.D. POSTDOCTORAL RESEARCH FELLOW, CENTER FOR PSYCHEDELIC & CONSCIOUSNESS RESEARCH

Adam Safron, Ph.D.

POSTDOCTORAL RESEARCH FELLOW, CENTER FOR PSYCHEDELIC & CONSCIOUSNESS RESEARCH

Dr. Adam Safron received his Ph.D. in Psychology from Northwestern University and is now a postdoctoral research fellow at Johns Hopkins Center for Psychedelic & Consciousness Research. As a researcher, he’s particularly interested in exploring how individual people can be free, creative, and adaptive in various parts of their lives. The majority of his work has focused on human motivation and preferences, though he’s also studied how brief mindfulness interventions can affect well-being and cognition. More recently, his work has expanded to include research into the many complex mechanisms behind psychedelics.

White X
headshot Garcia Romeu
Albert Garcia-Romeu, Ph.D. ASSISTANT PROFESSOR, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, PSYCHIATRY AND BEHAVIORAL SCIENCES

Albert Garcia-Romeu, Ph.D.

ASSISTANT PROFESSOR, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, PSYCHIATRY AND BEHAVIORAL SCIENCES

Dr. Albert Garcia-Romeu, who received his Ph.D. in Psychology from Sofia University, is an Assistant Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. His research has focused on how psychedelics, especially psilocybin, affect humans and specifically how this psychedelic drug may help treat substance use disorders. His main research interests include mindfulness, consciousness, spirituality and its connection to addiction and mental health, clinical uses for psychedelics, and beyond.

White X
Albert_Hofmann
Albert Hofmann, Ph.D. MEDICINAL CHEMISTRY, UNIVERSITY OF ZÜRICH, CREATOR OF LSD

Albert Hofmann, Ph.D.

MEDICINAL CHEMISTRY, UNIVERSITY OF ZÜRICH, CREATOR OF LSD

Dubbed the “Father of LSD,” Albert Hofmann was a Swiss chemist and the first to discover, synthesize, and use LSD—a groundbreaking discovery that changed the world and influenced countless psychiatrists. Despite it being criminalized by the U.S. Congress in 1966, Hofmann continued to advocate for the safe and therapeutic use of LSD for the remainder of his life.

White X
headshot-Alexander-Shulgin
Alexander “Sasha” Shulgin, Ph.D. CHEMIST, PHARMACOLOGIST, AND AUTHOR, PiHKAL and TiHKAL

Alexander “Sasha” Shulgin, Ph.D.

CHEMIST, PHARMACOLOGIST, AND AUTHOR, PiHKAL and TiHKAL

Alexander “Sasha” Shulgin, called the “godfather of psychedelics,” was a pharmacologist and chemist best known for introducing MDMA to psychologists for therapeutic use in the 1970s. Throughout his lifetime, he discovered, created, and used hundreds of novel psychedelic drugs. He and his wife, Ann Shulgin, authored two books, PiHKAL: A Chemical Love Story, which described nearly 180 psychedelic compounds and included instructions on how to make them, and TiHKAL, the sequel. Their goal in publishing these books was to ensure that the public had access to these discoveries and would be able to engage in self-exploration via psychedelics.

White X
headshot-Amanda-Feilding
Amanda Feilding FOUNDER, BECKLEY FOUNDATION

Amanda Feilding

FOUNDER, BECKLEY FOUNDATION

Amanda Feilding, a legendary advocate for LSD, founded the Beckley Foundation (originally the Foundation to Further Consciousness) in 1998, which is a non-profit organization devoted to researching drug policy reform and consciousness. She’s been involved in drug policy reform for more than 40 years, advocating for therapeutic psychedelic use, lobbying the United Nations, collaborating with policymakers and scientists to study the effects of psychedelics, and conducting research into their therapeutic benefits. Fielding has authored over 80 original scientific works and articles published in leading, peer-reviewed journals.

White X
Ann Shulgin
Ann Shulgin AUTHOR, PiHKAL and TiHKAL

Ann Shulgin

AUTHOR, PiHKAL and TiHKAL

Ann Shulgin, who was married to renowned chemist, Alexander “Sasha” Shulgin, was a legendary creator of designer novel psychedelic drugs. When MDMA and 2C-B were still legal, she worked as a lay therapist and used these substances in her therapy sessions. She was a lifelong advocate for the therapeutic use of psychedelics. In collaboration with her husband, she wrote two books, PiHKAL and TiHKAL, which made psychedelic synthesis accessible to laypeople who wanted to engage in self-exploration.

White X
headshot-Bill-Richards
Bill Richards, M. Div, S.T.M., Ph.D. PSYCHOLOGIST, CENTER FOR PSYCHEDELIC AND CONSCIOUSNESS RESEARCH

Bill Richards, M. Div, S.T.M., Ph.D.

PSYCHOLOGIST, CENTER FOR PSYCHEDELIC AND CONSCIOUSNESS RESEARCH

William “Bill” Richards is a psychologist at Johns Hopkins Center for Psychedelic and Consciousness Research and co-founder and chief therapist of Sunstone Therapies. He is one of the most influential modern researchers in the psychedelic field, having conducted research on psilocybin and its use in treating depression, anxiety, and addiction. Dr. Richards initiated some of the first, and most groundbreaking, research into LSD, DPT, MDA and psilocybin at the Maryland Psychiatric Research Center from 1967 to 1977. His book, Sacred Knowledge: Psychedelics and Religious Experience, explores the effects of psychedelics on consciousness, biological processes, and religious experiences.

White X
headshot-Bob-Jesse
Bob Jesse ADVISOR, CO-FOUNDER, JOHN HOPKINS UNIVERSITY DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES, THE COUNCIL ON SPIRITUAL PRACTICES

Bob Jesse

ADVISOR, CO-FOUNDER, JOHN HOPKINS UNIVERSITY DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES, THE COUNCIL ON SPIRITUAL PRACTICES

Robert “Bob” Jesse is a prominent researcher in the field of psychedelics research and therapy. Through his work at the Council on Spiritual Practices, a nonprofit centered on psychedelics research and spiritual development, he helped create the psilocybin research team at Johns Hopkins University. Jesse’s advocacy efforts have been instrumental in increasing public awareness related to psychedelic-assisted therapy. In 2017, he was awarded the Psychedelic Science Award by the Multidisciplinary Association for Psychedelic Studies (MAPS).

White X
headshot-Charles-Raison
Charles Raison, M.D. DIRECTOR, CENTER FOR COMPASSION STUDIES, COLLEGE OF SOCIAL AND BEHAVIORAL SCIENCES AT THE UNIVERSITY OF ARIZONA, CLINICAL AND TRANSLATIONAL RESEARCH, USONA INSTITUTE

Charles Raison, M.D.

DIRECTOR, CENTER FOR COMPASSION STUDIES, COLLEGE OF SOCIAL AND BEHAVIORAL SCIENCES AT THE UNIVERSITY OF ARIZONA, CLINICAL AND TRANSLATIONAL RESEARCH, USONA INSTITUTE

Dr. Charles Raison is a researcher and psychiatrist known for studying psychedelics as a potential treatment for major depressive disorder. He has received many teaching awards, as well as funding from the Centers for Disease Control and Prevention (CDC), National Center for Complementary and Alternative Medicine (NCCIH), and the National Institute of Mental Health (NIMH). His contributions to psychedelic-assisted therapy for depression have paved the way for addressing treatment-resistant depression.

White X
headshot-David-Erritzoe
David Erritzoe, M.D., Ph.D., MRCPsych DEPUTY HEAD AND CLINICAL DIRECTOR, CENTRES FOR NEUROPSYCHOPHARMACOLOGY AND PSYCHEDELIC RESEARCH, IMPERIAL COLLEGE LONDON

David Erritzoe, M.D., Ph.D., MRCPsych

DEPUTY HEAD AND CLINICAL DIRECTOR, CENTRES FOR NEUROPSYCHOPHARMACOLOGY AND PSYCHEDELIC RESEARCH, IMPERIAL COLLEGE LONDON

Dr. David Erritzoe is a researcher, psychiatrist, and clinical director for the Centres for Psychedelic Research (CPR) at Imperial College London. He has collaborated with Dr. Robin Carhart-Harris and Professor David Nutt at CPR to research the therapeutic potential of ketamine, MDMA, and classic psychedelics. In early 2021, he started a new NHS-based psychopharmacology and psychedelic research clinic, the CIPPRes Clinic, at St. Charles Hospital in London. Dr. Erritzoe is one of the leading scientists studying the effects of psychedelics like psilocybin for end-of-life anxiety and the efficacy of microdosing.

White X
David Mathai
David Mathai, M.D. POST-DOCTORAL RESEARCH FELLOW, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

David Mathai, M.D.

POST-DOCTORAL RESEARCH FELLOW, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

David Mathai is a post-doctoral research fellow in the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine and works as a psychiatrist for Addiction Treatment Services and a guide for psilocybin-assisted therapy. He has studied the antidepressant effects of ketamine, and his current research focuses on the therapeutic use of psychedelics in facilitating change.

White X
headshot-David-Nichols
David Nichols, Ph.D. FOUNDER, ADJUNCT PROFESSOR, HEFFTER RESEARCH INSTITUTE, UNIVERSITY OF NORTH CAROLINA CHAPEL HILL

David Nichols, Ph.D.

FOUNDER, ADJUNCT PROFESSOR, HEFFTER RESEARCH INSTITUTE, UNIVERSITY OF NORTH CAROLINA CHAPEL HILL

David Nichols is a pharmacologist, medicinal chemist, and professor who has been researching psychedelics since 1969. In 1993, he founded the Heffter Research Institute, which promotes research related to classic hallucinogens and psychedelics, primarily psilocybin, exploring the therapeutic potential for addiction and easing cancer-related distress. This organization also supports studies surrounding the effects of psychedelics on behavior, cognition, and neurological activity. Nichols’ research and efforts have helped pave the way for profound healing through psychedelics.

White X
headshot-David-Nutt
David Nutt, M.D., D.M., FRCP, FRCPsych, FSB, FMedSci FOUNDER AND CHAIR, DEPARTMENT OF BRAIN SCIENCES IMPERIAL COLLEGE LONDON, DRUGSCIENCE

David Nutt, M.D., D.M., FRCP, FRCPsych, FSB, FMedSci

FOUNDER AND CHAIR, DEPARTMENT OF BRAIN SCIENCES IMPERIAL COLLEGE LONDON, DRUGSCIENCE

Dr. David Nutt is a neuropsychopharmacologist from England specializing in researching psychedelics like LSD and psilocybin and their potential use in treating neurological and mental health disorders. He has also spent significant time advocating for evidence-based drug policy reform. His book, Drugs Without the Hot Air, which explores and interrogates drug policy and harms, won the Salon London Transmission Prize in 2014. Dr. Nutt is currently the Chair of DrugScience and President of the European Brain Council. He has published over 400 original research papers and 27 books.

White X
headshot David Yaden
David Yaden, Ph.D. ASSISTANT PROFESSOR, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

David Yaden, Ph.D.

ASSISTANT PROFESSOR, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Dr. David Yaden is an assistant professor at Johns Hopkins University School of Medicine in the Department of Psychiatry and Behavioral Sciences and also works in the Center for Psychedelic and Consciousness Research, studying the psychopharmacology, cognitive neuroscience, and psychology of transformative psychedelic experiences. Dr. Yaden’s research interests lie in understanding how psychedelic experiences can lead to long-term transformations as well as the therapeutic potential of psychedelic drugs for addiction and mood disorders.

White X
headshot-Dennis-McKenna
Dennis McKenna, Ph.D. FOUNDER AND PRESIDENT, THE MCKENNA ACADEMY

Dennis McKenna, Ph.D.

FOUNDER AND PRESIDENT, THE MCKENNA ACADEMY

Dennis McKenna is an ethnopharmacologist, author, lecturer, and advocate for psychedelics use who founded the McKenna Academy of Natural Philosophy in 2018. This nonprofit is devoted to researching Amazonian ethnomedicines, psychedelics, consciousness, preserving Indigenous knowledge, and beyond. McKenna is also a founding board member of the Heffter Research Institute, an organization devoted to psychedelics research. He was also a researcher on the Hoasca Project, the first biomedical study of the long-term use of ayahuasca and its therapeutic potential.

White X
headshot Erika Dyck
Erika Dyck, Ph.D., M.A. PROFESSOR AND CANADA RESEARCH CHAIR, UNIVERSITY OF SASKATCHEWAN

Erika Dyck, Ph.D., M.A.

PROFESSOR AND CANADA RESEARCH CHAIR, UNIVERSITY OF SASKATCHEWAN

Dr. Erika Dyck, Professor and Canada Research Chair in the History of Health & Social Justice Department at the University of Saskatchewan, has contributed significantly to the psychedelic research and educational space. Her research has focused on psychedelic drugs, including LSD, and the history of psychiatry, medicine, health, eugenics, and reproductive rights. She is the author of many books, including Psychedelic Psychiatry: LSD from Clinic to Campus.

White X
headshot-Franz-X-Vollenweider
Franz X. Vollenweider, M.D. CO-DIRECTOR, PROFESSOR, AND DIRECTOR, CENTRE FOR PSYCHIATRIC RESEARCH UNIVERSITY OF ZURICH

Franz X. Vollenweider, M.D.

CO-DIRECTOR, PROFESSOR, AND DIRECTOR, CENTRE FOR PSYCHIATRIC RESEARCH UNIVERSITY OF ZURICH

At the University of Zurich, Franz X. Vollenweider is Professor of Psychiatry in the School of Medicine, Director of the Neuropsychopharmacology and Brain Imaging Unit, and Co-Director of the Center for Psychiatric Research. He founded the Heffter Research Center Zurich for Consciousness Studies in 1998 and currently serves as the Director. Vollenweider’s research into the short and long-term effects of LSD and psilocybin on social interaction, emotional regulation, brain function, and the sense of self has been groundbreaking.

White X
headshot-Frederick-Barrett
Frederick S. Barrett, Ph.D. ASSOCIATE PROFESSOR, PSYCHIATRY AND BEHAVIORAL SCIENCES, JOHNS HOPKINS SCHOOL OF MEDICINE

Frederick S. Barrett, Ph.D.

ASSOCIATE PROFESSOR, PSYCHIATRY AND BEHAVIORAL SCIENCES, JOHNS HOPKINS SCHOOL OF MEDICINE

Frederick S. Barrett, a cognitive neuroscientist and a psychedelic trailblazer, is an Associate Center Director at the Center for Psychedelic and Consciousness Research. Since 2013, he’s been conducting research at Johns Hopkins University on the effects of psychedelic drugs in healthy patients and those with substance use and mood disorders. In 2017, he received an NIH grant to study the biological effects of psilocybin, the first federally funded research of its kind since the 1970s.

White X
headshot-Gunther-Weil
Gunther M. Weil, Ph.D. CO-FOUNDER AND CEO, VALUE MENTORS

Gunther M. Weil, Ph.D.

CO-FOUNDER AND CEO, VALUE MENTORS

Gunter M. Weil is a psychologist, executive coach, organizational consultant, educator, and self-proclaimed student of consciousness. In graduate school, he was one of the main members of the Harvard Psilocybin Project between 1960 and 1962, working closely with legendary psychologist and psychedelic advocate Timothy Leary, as well as Ralph Metzner and Richard Alpert. His work on this project helped create awareness for the spiritual and therapeutic benefits of psilocybin.

White X
headshot-Hamilton-Morris
Hamilton Morris CONSULTANT, COMPASS PATHWAYS

Hamilton Morris

CONSULTANT, COMPASS PATHWAYS

Hamilton Morris is a research scientist, filmmaker, and journalist known for creating and directing the series, Hamilton’s Pharmacopeia, which explores the cultural impact, chemistry, and history of various psychoactive drugs, especially psychedelics. In 2021, he became a consultant for COMPASS Pathways, where he advises on the therapeutic potential of psychedelics therapy for those with psychiatric disorders.

White X
headshot-Harriet-de-Wit
Harriet de Wit, Ph.D. PROFESSOR AND DIRECTOR, THE HUMAN BEHAVIORAL PHARMACOLOGY LABORATORY, UNIVERSITY OF CHICAGO, COMMITTEE ON CLINICAL PHARMACOLOGY AND PHARMACOGENOMICS

Harriet de Wit, Ph.D.

PROFESSOR AND DIRECTOR, THE HUMAN BEHAVIORAL PHARMACOLOGY LABORATORY, UNIVERSITY OF CHICAGO, COMMITTEE ON CLINICAL PHARMACOLOGY AND PHARMACOGENOMICS

Harriet de Wit has been researching psychoactive drugs for more than four decades. She has conducted innovative and groundbreaking research in the field of psychedelics, including a project investigating the effects of LSD and MDMA on brain function and mood. Her research has been funded by the NIH, and she has trained countless students and post-doctoral fellows and published more than 300 scientific papers. In 2019, she received the Distinguished Investigator Award of the European Behavioral Pharmacology Society.

White X
headshot-James-Fadiman
James Fadiman, Ph.D. CO-FOUNDER, AUTHOR, INSTITUTE OF TRANSPERSONAL PSYCHOLOGY, THE PSYCHEDELIC EXPLORER’S GUIDE

James Fadiman, Ph.D.

CO-FOUNDER, AUTHOR, INSTITUTE OF TRANSPERSONAL PSYCHOLOGY, THE PSYCHEDELIC EXPLORER’S GUIDE

James Fadiman has been a researcher and proponent for psychedelic microdosing for over 50 years. In the 1960s he was a member of the research team that conducted the “psychedelics in problem-solving” experiment at the International Foundation for Advanced Study. He co-founded the Institute of Transpersonal Psychology, now known as Sofia University, in 1975, where he lectured on psychedelics. His book, The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys, discusses safe practices for psychedelic use and highlights the therapeutic, healing, and scientific potential of these substances. Dr. Fadiman also created the Fadiman protocol, an original technique for microdosing psychedelics.

White X
headshot James Rucker
James Rucker, Ph.D. CONSULTANT PSYCHIATRIST AND SENIOR CLINICAL LECTURER, KING’S COLLEGE LONDON

James Rucker, Ph.D.

CONSULTANT PSYCHIATRIST AND SENIOR CLINICAL LECTURER, KING’S COLLEGE LONDON

Dr. James Rucker is currently a consultant psychiatrist and senior clinical lecturer at the Centre for Affective Disorders at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. He currently pilots the Psychedelic Trials Group along with Professor Allan Young, where they run clinical trials with MDMA, DMT, and psilocybin. In 2017, he was awarded an NIHR Clinician Scientist Fellowship to study the efficacy and safety of psilocybin. His expertise and research interests include new psychopharmacological approaches to treating mood disorders and psychedelic-assisted therapy with ketamine, cannabinoids, MDMA, and other psychedelics.

White X
headshot Kim Kuypers
Kim Kuypers, Ph.D. ASSOCIATE PROFESSOR AND RESEARCHER, MAASTRICHT UNIVERSITY

Kim Kuypers, Ph.D.

ASSOCIATE PROFESSOR AND RESEARCHER, MAASTRICHT UNIVERSITY

Dr. Kim Kuypers is an Associate Professor at Maastricht University, at the Faculty of Psychology and Neuroscience. Her research interests lie in psychedelics like MDMA and how they impact neurological mechanisms, hormones, creativity, and social cognition. Dr. Kuypers is also an advisor and scientific collaborator for MindMed, a psychedelic drug research company, where she leads many of the clinical trials, including research about LSD for the treatment of ADHD.

White X
headshot Luis Eduardo Luna
Luis Eduardo Luna, Ph.D. DIRECTOR, WASIWASKA RESEARCH CENTER

Luis Eduardo Luna, Ph.D.

DIRECTOR, WASIWASKA RESEARCH CENTER

Dr. Luis Eduardo Luna, who is Guggenheim Fellow and Fellow of the Linnean Society of London, is an anthropologist, author, and ayahuasca researcher. Currently, he is the director of Wasiwaska Research Center, a research center in Brazil that studies consciousness, visionary art, Indigenous spirituality, and psychedelic plants. He received his Ph.D. from the Institute of Comparative Religion at Stockholm University and an honorary doctorate from St. Lawrence University. He has written, co-written, and edited several psychedelic-related books, including Ayahuasca Reader: Encounters with the Amazon’s Sacred Vine, Inner Paths to Outer Space: Journeys Through Psychedelics and Other Spiritual Technologies, and Vegetalismo: Shamanism Among the Mestizo Population of the Peruvian Amazon.

White X
headshot Margaret Ross
Margaret Ross, Psy.D. SENIOR CLINICAL PSYCHOLOGIST, ST. VINCENT’S HOSPITAL

Margaret Ross, Psy.D.

SENIOR CLINICAL PSYCHOLOGIST, ST. VINCENT’S HOSPITAL

Dr. Margaret Ross is the Clinical Lead and Chief Principal Investigator for the first psilocybin-assisted treatment study in Australia studying its use in treating anxiety and depression in terminally ill individuals. Her work is truly groundbreaking in the cancer and palliative care space. Prior to this work, she was a research psychologist and clinical trial coordinator for The University of Melbourne and Orygen Youth Health.

White X
headshot-Mary-Cosimano
Mary Cosimano, LMSW DIRECTOR OF GUIDE/FACILITATOR SERVICES, JOHNS HOPKINS CENTER FOR PSYCHEDELIC AND CONSCIOUSNESS RESEARCH

Mary Cosimano, LMSW

DIRECTOR OF GUIDE/FACILITATOR SERVICES, JOHNS HOPKINS CENTER FOR PSYCHEDELIC AND CONSCIOUSNESS RESEARCH

Mary Cosimano serves as a Director of Guide/Facilitator Services at Johns Hopkins Center for Psychedelic and Consciousness Research where she supervises and trains Session Facilitators for psilocybin-assisted therapy. Previously, she was a Session Facilitator and was involved with over 475 psilocybin study sessions. She also teaches at California Institute to Integral Studies for their Psychedelic-Assisted Therapies and Research program and trains therapists in psychedelic psychotherapy.

White X
headshot-Matthew-Johnson
Matthew Johnson, Ph.D. SUSAN HILL WARD PROFESSOR IN PSYCHEDELICS AND CONSCIOUSNESS, PROFESSOR OF PSYCHIATRY AND BEHAVIORAL SCIENCES , JOHN HOPKINS UNIVERSITY

Matthew Johnson, Ph.D.

SUSAN HILL WARD PROFESSOR IN PSYCHEDELICS AND CONSCIOUSNESS, PROFESSOR OF PSYCHIATRY AND BEHAVIORAL SCIENCES , JOHN HOPKINS UNIVERSITY

As one the most published scientists on psychedelics’ effects in humans, Matthew Johnson’s influence on the field of psychedelics has been profound. In 2014, he published the first research related to treating tobacco addiction with psychedelics, and in 2016, he and his colleagues published the biggest psilocybin study on treating cancer-related distress. He has also researched the therapeutic potential of psilocybin for opioid dependence and post-traumatic stress disorder (PTSD).

White X
headshot-Matthew-Wall
Matthew Wall, M.D. SENIOR LECTURER, FACULTY OF MEDICINE, DEPARTMENT OF METABOLISM, DIGESTION AND REPRODUCTION, IMPERIAL COLLEGE LONDON

Matthew Wall, M.D.

SENIOR LECTURER, FACULTY OF MEDICINE, DEPARTMENT OF METABOLISM, DIGESTION AND REPRODUCTION, IMPERIAL COLLEGE LONDON

Dr. Matthew Wall is a cognitive neuroscientist whose current research focuses on the neurological effects of psychedelics, cannabis, and sex hormones. He has conducted studies on the therapeutic mechanisms of psilocybin for treatment-resistant depression, the neuropsychopharmacology of cannabis, the effects of LSD, MDMA on brain function, the impact of ecstasy on cooperativity, and more. His research is undoubtedly advancing scientific knowledge of psychedelics and expanding the possibilities for the future.

White X
headshot-Natalie-Gukasyan
Natalie Gukasyan, M.D. ASSISTANT PROFESSOR AND MEDICAL DIRECTOR, JOHNS HOPKINS UNIVERSITY

Natalie Gukasyan, M.D.

ASSISTANT PROFESSOR AND MEDICAL DIRECTOR, JOHNS HOPKINS UNIVERSITY

Dr. Natalie Gukasyan, an Assistant Professor, Medical Director, and psychiatrist at Johns Hopkins University, has conducted research on the efficacy of psilocybin-assisted psychotherapy for eating disorders, substance use disorders, and mood disorders. She has also published research related to menstrual changes and reversal of amenorrhea (resumption of menstruation after its absence) as induced by classic psychedelics. Her research is helping to expand our understanding of psychedelic medicine and its many clinical uses.

White X
headshot-Nigel-Strauss
Nigel Strauss, M.D. MEDICAL DIRECTOR, MILLSWYN CLINIC

Nigel Strauss, M.D.

MEDICAL DIRECTOR, MILLSWYN CLINIC

Nigel Strauss is an Australian psychiatrist, psychedelics researcher, advocate, and MAPS-accredited psychedelic-assisted psychotherapist, who has published considerable research on the therapeutic use of psychedelics. He’s currently leading a clinical trial in Melbourne on psilocybin-assisted psychotherapy for people struggling with treatment-resistant depression. Within the Australian College of Psychiatrists, he is advocating for psychedelic use in psychiatric practices throughout the country.

White X
headshot Pamela Kryskow
Pamela Kryskow, M.D. CO-FOUNDER & SCIENTIFIC AND MEDICAL ADVISOR, MYCOMEDICA LIFE SCIENCES

Pamela Kryskow, M.D.

CO-FOUNDER & SCIENTIFIC AND MEDICAL ADVISOR, MYCOMEDICA LIFE SCIENCES

Dr. Pamela Kryskow is a founding member of the Psychedelic Association of Canada, and the co-founder and scientific and medical advisor for MycoMedica Life Sciences. As part of her practice, Dr. Kryskow focuses on furthering research and development of psychedelic medicine, including psilocybin and MDMA-assisted psychotherapy. Dr. Kryskow is a frequent public speaker, with a focus on research and the ethical implications of psychedelic medicine.

White X
headshot-Paul-Stamets
Paul Stamets HONORARY DOCTORATE, FOUNDER, NATIONAL UNIVERSITY OF NATURAL MEDICINE, FUNGI PERFECTI

Paul Stamets

HONORARY DOCTORATE, FOUNDER, NATIONAL UNIVERSITY OF NATURAL MEDICINE, FUNGI PERFECTI

Paul Stamets is a renowned mycologist, author, and speaker who has lectured all over the world about the many benefits of mushrooms, including psilocybin, even naming several new species of psilocybin mushrooms. In 1980, he founded Fungi Perfecti, a business devoted to cultivating safe and high-quality mushrooms. Stamets is the author of six books, including Psilocybin Mushrooms of the World, Growing Gourmet and Medicinal Mushrooms, and Mycelium Running: How Mushrooms Can Help Save the World. He is also the creator of the Stamets Stack, a unique microdosing methodology utilizing psilocybin mushrooms.

White X
headshot-Rachel-Yehuda
Rachel Yehuda, Ph.D. PROFESSOR OF NEUROSCIENCE AND PSYCHIATRY, VICE CHAIR OF VETERANS AFFAIRS, CAHN SCHOOL OF MEDICINE, MOUNT SINAI UNIVERSITY

Rachel Yehuda, Ph.D.

PROFESSOR OF NEUROSCIENCE AND PSYCHIATRY, VICE CHAIR OF VETERANS AFFAIRS, CAHN SCHOOL OF MEDICINE, MOUNT SINAI UNIVERSITY

Dr. Rachel Yehuda is a professor of neuroscience and psychiatry at Mount Sinai School of Medicine and the director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai. She is the author of over 500 papers on PTSD and the psychology of trauma, and she has investigated psychedelic-assisted psychotherapy approaches for PTSD and the biological influences that may affect treatment outcomes. Yehuda’s work could pave the way for groundbreaking treatment methods for people struggling with PTSD.

White X
headshot-Rick-Doblin
Rick Doblin, Ph.D. FOUNDER AND PRESIDENT, MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES (MAPS)

Rick Doblin, Ph.D.

FOUNDER AND PRESIDENT, MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES (MAPS)

Rick Doblin is the founder and president of Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit organization created to increase awareness and knowledge related to psychedelic drugs. MAPS has provided $20 million in funding toward medical cannabis and psychedelics research and education efforts, thanks to Doblin’s vision and advocacy. Doblin has made it his life’s work to help legalize the therapeutic use of marijuana and psychedelics.

White X
headshot-Rick-Strassman
Rick Strassman, M.D. AUTHOR, DMT: THE SPIRIT MOLECULE

Rick Strassman, M.D.

AUTHOR, DMT: THE SPIRIT MOLECULE

Rick Strassman is an Associate Professor of Psychiatry at the University of New Mexico School of Medicine. After a 20-year intermission, Strassman was the first person in the United States to conduct psychedelics research on humans, with his studies related to DMT. His research led to authoring the book, DMT: The Spirit Molecule, which discusses his research and conclusions. His book, which has sold over 100,000 copies and been translated into 12 languages, has been foundational in understanding the effects of DMT.

White X
headshot-Robin-Carhart-Harris
Robin Carhart-Harris, Ph.D. DIRECTOR PSYCHEDELICS DIVISION, NEUROSCAPE, UNIVERSITY OF CALIFORNIA SAN FRANCISCO

Robin Carhart-Harris, Ph.D.

DIRECTOR PSYCHEDELICS DIVISION, NEUROSCAPE, UNIVERSITY OF CALIFORNIA SAN FRANCISCO

In 2019, Dr. Robin Carhart-Harris founded and served as the Head of the Centre for Psychedelic Research at Imperial College London, where he studied the therapeutic use of MDMA, LSD, and psilocybin. Some of his most significant contributions as a psychedelic researcher include the entropic brain hypothesis related to psychedelic substance use, research on using psilocybin to treat addiction, anxiety, and depression, and studies investigating the effects of LSD on the brain. Dr. Carhart-Harris is also the Scientific Director of Maya Health. He currently serves as the Director of the Psychedelics Division, Neuroscape, at UCSF.

White X
Roland Griffiths
Roland Griffiths, Ph.D. PROFESSOR IN THE DEPARTMENTS OF PSYCHIATRY AND NEUROSCIENCES, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Roland Griffiths, Ph.D.

PROFESSOR IN THE DEPARTMENTS OF PSYCHIATRY AND NEUROSCIENCES, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Roland Griffiths is a professor and the founding Director of the Johns Hopkins Center on Psychedelic and Consciousness Research. As a psychedelic researcher and scientist, he has contributed significantly to the psychedelics field. In 1999, he created a research program exploring the effects of psilocybin on healthy volunteers, in mediators, and in religious leaders. His research has also investigated the therapeutic benefits of psilocybin for major depression, cancer-related distress, and quitting smoking.

White X
headshot-Rosalind-Watts
Rosalind Watts, Ph.D. FOUNDER, ACER INTEGRATION

Rosalind Watts, Ph.D.

FOUNDER, ACER INTEGRATION

Rosalind Watts has contributed significantly to the advancement of psychedelics research. She has worked as the Clinical Lead for Imperial College London’s psilocybin for depression trial. Most recently, she created ACER Integration, which is a community that allows people to contextualize their experiences and complex emotions after using psychedelics.

White X
headshot Sandeep Nayak
Sandeep Nayak, M.D. ASSISTANT PROFESSOR, JOHNS HOPKINS CENTER FOR PSYCHEDELIC & CONSCIOUSNESS RESEARCH

Sandeep Nayak, M.D.

ASSISTANT PROFESSOR, JOHNS HOPKINS CENTER FOR PSYCHEDELIC & CONSCIOUSNESS RESEARCH

Dr. Sandeep Nayak received his MD from Brown University and completed his psychiatry residency at Johns Hopkins Hospital, where he is now an Assistant Professor and psychedelics researcher at the Center for Psychedelic & Consciousness Research. He primarily studies the potential of psychedelics for the treatment of mood disorders and addiction, though he also researches psychedelic-belief changes and works as a psychiatrist at the Center for Addiction and Pregnancy and Addiction Treatment Services.

White X
headshot-Stanislav-grof
Stanislav Grof, M.D., Ph.D. PSYCHIATRIST, CALIFORNIA INSTITUTE OF INTEGRAL STUDIES

Stanislav Grof, M.D., Ph.D.

PSYCHIATRIST, CALIFORNIA INSTITUTE OF INTEGRAL STUDIES

Stanislav Grof, who was born in Prague, is a psychiatrist and psychedelic pioneer with more than 60 years of experience studying non-typical states of consciousness. He is one of the founders of transpersonal psychology, also called spiritual psychology. Grof’s psychedelic research has helped to reveal the therapeutic potential of LSD, DMT, and other psychedelics. After LSD was made illegal, Grof continued his research without LSD and developed “holotropic breathwork,” a breathing technique intended to facilitate emotional healing and growth. Dr. Grof is also the Founder and Director of the Forum on Religion and Ecology, and has published over 150 papers and original scientific works as well as several books, such as Realms of the Human Unconscious, Beyond the Brain, and LSD Psychotherapy.

White X
headshot Vince Polito
Vince Polito, Ph.D. SENIOR LECTURER AND SENIOR RESEARCH FELLOW, SCHOOL OF PSYCHOLOGICAL SCIENCES MACQUARIE UNIVERSITY

Vince Polito, Ph.D.

SENIOR LECTURER AND SENIOR RESEARCH FELLOW, SCHOOL OF PSYCHOLOGICAL SCIENCES MACQUARIE UNIVERSITY

Dr. Vince Polito is a cognitive scientist, senior lecturer, and senior research fellow at Macquarie University, Australia, in the School of Psychological Sciences, where he got his Ph.D. He has significant experience conducting research on psilocybin microdosing, having led one of the biggest systematic studies to date. His other research interests include altered states of consciousness, body representation in virtual reality, and how expectations and beliefs affect psychedelic journeys.

White X

Pop Culture

headshot-Alan-Watts
Alan Watts, M.A. THEOLOGY, SEABURY-WESTERN THEOLOGICAL SEMINARY, HONORARY DOCTORATE IN DIVINITY, UNIVERSITY OF VERMONT

Alan Watts, M.A.

THEOLOGY, SEABURY-WESTERN THEOLOGICAL SEMINARY, HONORARY DOCTORATE IN DIVINITY, UNIVERSITY OF VERMONT

Alan Watts was a groundbreaking psychonaut and advocate for human psychedelic use who first began exploring psychedelics in the 1950s. As the author of The Joyous Cosmology: Adventures in the Chemistry of Consciousness, The Way of Zen, The Wisdom of Insecurity, and over 20 other books, Watts was a leading psychedelic philosopher. Despite passing away fifty years ago, his many talks and lectures on the nature of reality, psychedelics, and the human experience continue to profoundly impact the psychedelic community and pop culture today.

White X
headshot-Alex-Grey
Alex Grey CO-FOUNDER, CHAPEL OF SACRED MIRRORS (COSM)

Alex Grey

CO-FOUNDER, CHAPEL OF SACRED MIRRORS (COSM)

Alex Grey is a famous and influential artist in the visionary art movement, creating psychedelic paintings with mystical and spiritual themes. His work has largely been inspired by the journeys he takes on LSD, which allowed him to get in touch with his divine spirit and create work that reflects the transcendency of mind, body, and spirit. Inspired by his psychedelic experiences, he also hosts lectures on psychedelic therapy and hosts full moon gatherings at his chapel, which involve art classes, psychedelic information, and guided meditations.

White X
headshot-Bett-Williams
Bett Williams GUIDE, FACILITATOR, AUTHOR, THE WILD KINDNESS: A PSILOCYBIN ODYSSEY

Bett Williams

GUIDE, FACILITATOR, AUTHOR, THE WILD KINDNESS: A PSILOCYBIN ODYSSEY

Bett Williams is a psychedelics pioneer, explorer, and author of The Wild Kindness: A Psilocybin Odyssey, a memoir about growing psilocybin mushrooms in New Mexico. She co-hosts a podcast with her partner, Beth Hill, called No Cures, Only Alchemy, which centers discussions about psychedelics. Her memoir and podcast make discussions about the benefits of psilocybin accessible to a new generation of readers and listeners.

White X
headshot-Brian-Muraresku
Brian Muraresku AUTHOR, THE IMMORTALITY KEY: THE SECRET HISTORY OF THE RELIGION WITH NO NAME

Brian Muraresku

AUTHOR, THE IMMORTALITY KEY: THE SECRET HISTORY OF THE RELIGION WITH NO NAME

Brian Muraresku is the author of the New York Times bestseller, The Immortality Key, a groundbreaking exploration of the history of psychedelics and how they have influenced the origins of Western civilization and religion. The book covers a 10-year investigation into the “lost, psychedelic sacrament of Greek religion to early Christianity,” exposing many buried truths and reinvigorating a 40-year-old claim that the original Christian Eucharist was psychedelic.

White X
headshot-Deborah-Snyder
Deborah Snyder FOUNDER AND CEO, SYNERGETIC PRESS

Deborah Snyder

FOUNDER AND CEO, SYNERGETIC PRESS

Deborah Snyder founded Synergetic Press in 1984, committed to publishing breakthrough books on psychedelics, consciousness, cultural anthropology, the environment, and ethnobotany. Some notable psychedelic books include Psychedelic Integration: Psychotherapy for Non-Ordinary States of Consciousness by Marc B. Aixalà, Psychedelic Justice: Toward a Diverse and Equitable Psychedelic Culture edited by Clancy Cavnar and Beatriz Caiuby Labate, The Way of the Psychonaut by Stanislav Grof, and The Nature of Drugs: History, Pharmacology, and Social Impact by Alexander “Sasha” Shulgin and Ann Shulgin.

White X
headshot-Duncan-Trussell
Duncan Trussell PODCASTER, COMEDIAN AND ACTOR, THE MIDNIGHT GOSPEL

Duncan Trussell

PODCASTER, COMEDIAN AND ACTOR, THE MIDNIGHT GOSPEL

Duncan Trussell is a comic and actor known for his podcast, The Duncan Trussell Family Hour, and his Netflix show, The Midnight Gospel. He is a huge proponent of psychedelics and has been very vocal about his positive experience with ketamine therapy for his depression and trauma, which has helped to destigmatize mental illness and the use of psychedelics for healing.

White X
headshot-Gabor-Mate
​​Gabor Maté, M.D., C.M. ​​AUTHOR, IN THE REALM OF HUNGRY GHOSTS: CLOSE ENCOUNTERS WITH ADDICTION

​​Gabor Maté, M.D., C.M.

​​AUTHOR, IN THE REALM OF HUNGRY GHOSTS: CLOSE ENCOUNTERS WITH ADDICTION

Gabor Mate is a bestselling author, renowned speaker, and doctor with specializations in trauma, stress, developmental psychology, childhood development, cancer, addiction, ADHD, and many other conditions and areas of study. He is an advocate for the use of psychedelics in treating substance addiction, cancer, and PTSD, and has given countless speeches about the transformative healing power of psychedelic-assisted therapy.

White X
headshot-Joe-Moore
Joe Moore CO-FOUNDER AND CEO, PSYCHEDELICS TODAY

Joe Moore

CO-FOUNDER AND CEO, PSYCHEDELICS TODAY

Joe Moore co-founded Psychedelics Today, an organization and media platform that centers on psychedelic media, education, and advocacy. He is the host of the associated podcast, in which he interviews industry leaders on various topics related to psychedelics, such as their therapeutic potential, legislation status, harm reduction, and more.

White X
headshot-Joe-Rogan
Joe Rogan PODCASTER, THE JOE ROGAN EXPERIENCE,

Joe Rogan

PODCASTER, THE JOE ROGAN EXPERIENCE,

Joe Rogan is a famous podcaster, comic, and self-proclaimed “psychedelic adventurer.” He frequently discusses psychedelics like DMT, LSD, psilocybin, and mescaline on his podcast with various experts and psychedelic pioneers. With 12.8 million subscribers, Joe’s conversations and interviews about psychedelics are influential in the world of psychedelic use and self-exploration.

White X
headshot-Julie-Holland
Julie Holland, M.D. PSYCHIATRIST, PSYCHOPHARMACOLOGIST, AUTHOR, GOOD CHEMISTRY: THE SCIENCE OF CONNECTION FROM SOUL TO PSYCHEDELICS

Julie Holland, M.D.

PSYCHIATRIST, PSYCHOPHARMACOLOGIST, AUTHOR, GOOD CHEMISTRY: THE SCIENCE OF CONNECTION FROM SOUL TO PSYCHEDELICS

Julie Holland is a psychiatrist and psychopharmacologist who currently serves as a medical monitor to Multidisciplinary Association for Psychedelics Studies (MAPS). She has worked on many clinical studies exploring the efficacy of cannabis and MDMA in the treatment of PTSD. She wrote the book, Good Chemistry: The Science of Connection from Soul to Psychedelics, which focuses on the importance of connection and how we can find it in community, meditation, and through psychedelics.

White X
headshot-Michael-Pollan
Michael Pollan PROFESSOR, AUTHOR OF HOW TO CHANGE YOUR MIND, UC BERKELEY

Michael Pollan

PROFESSOR, AUTHOR OF HOW TO CHANGE YOUR MIND, UC BERKELEY

Michael Pollan is a 2022-2023 Guggenheim Fellow and an accomplished author of eight books, including How to Change Your Mind, which was an instant New York Times bestseller. This book, which was a mixture of journalism, history, botany, and reporting, focused on new research into the therapeutic benefits of psychedelics like psilocybin and LSD, and was key in moving forward psychedelic discourse. There is also a Netflix series of the same name.

White X
headshot-Ram-Dass
Ram Dass, Ph.D. RESEARCHER, AUTHOR, HARVARD UNIVERSITY

Ram Dass, Ph.D.

RESEARCHER, AUTHOR, HARVARD UNIVERSITY

Ram Dass (previously Dr. Richard Alpert) was a Harvard psychologist, spiritual leader, guru, and author. In the early 1960s, he conducted research with Timothy Leary on the therapeutic potential of psychedelics and collaborated with graduate student, Walter Pahnke, on his “Good Friday Experiment” which studied psychedelic drugs and spiritual experiences. Dass had a life-changing experience when he traveled to India and met Hindu guru, Neem Karoli Baba, who gave him his new name, inspiring him to lead a dharmic life. After that, he authored Be Here Now, which heavily influenced the spiritual movement.

White X
headshot-Sam-Harris
Sam Harris, Ph.D. NEUROSCIENTIST, AUTHOR OF WAKING UP: A GUIDE TO SPIRITUALITY WITHOUT RELIGION,

Sam Harris, Ph.D.

NEUROSCIENTIST, AUTHOR OF WAKING UP: A GUIDE TO SPIRITUALITY WITHOUT RELIGION,

Sam Harris is a neuroscientist, author, podcast host, philosopher, public speaker, and creator of the meditation app, Waking Up. His work covers a wide variety of scientific and spiritual topics, including psychedelics. His meditation app, Waking Up, includes guided meditations, and conversations about psychedelics, psychology, and meditation. On his podcast, he frequently invites guests on to discuss the latest psychedelics research. His latest book, Waking Up: A Guide to Spirituality Without Religion, he discusses the use of psychedelics and their effect on consciousness.

White X
headshot-Shelby-Hartman
Shelby Hartman CO-FOUNDER AND EDITOR-IN-CHIEF, DOUBLEBLIND

Shelby Hartman

CO-FOUNDER AND EDITOR-IN-CHIEF, DOUBLEBLIND

Shelby Hartman co-founded the biannual print magazine and media company, DoubleBlind, which covers the latest news and stories about global psychedelics use and research. Her work has appeared in Rolling Stone, VICE, the Huffington Post, and beyond, and her features have covered topics like the cannabis industry, the psychedelic research boom, ayahuasca’s popularity, and PTSD among veterans.

White X
headshot-Terence-McKenna
Terence McKenna PHILOSOPHER, ETHNOBOTANIST, AUTHOR,

Terence McKenna

PHILOSOPHER, ETHNOBOTANIST, AUTHOR,

Commonly called the “Timothy Leary of the ‘90s,” Terence McKenna was a mystic, philosopher, ethnobotanist, public speaker, author, psychedelic pioneer, and advocate for the use of psychedelic plants. He wrote extensively about psychedelic drugs, shamanism, philosophy, environmentalism, human consciousness, and more. He and his brother, Dennis, developed a technique for growing psilocybin mushrooms using spores from the Amazon and published their findings in Psilocybin: Magic Mushroom Grower’s Guide.

White X
headshot-Tim-Ferriss
Tim Ferriss PODCAST HOST, THE TIM FERRISS SHOW

Tim Ferriss

PODCAST HOST, THE TIM FERRISS SHOW

Tim Ferriss is a bestselling author, investor, entrepreneur, and host of the podcast, The Tim Ferriss Show, which has had over 900 million downloads and has introduced psychedelics information, including microdosing, scientific research, mind-enhancing methods, and legal information, to millions of people. He has had many notable psychedelic researchers as guests on his podcast. He has also donated over $2 million for clinical research related to psychedelic substances.

White X
headshot-Timothy-Leary
Timothy Leary RESEARCHER, PROFESSOR, HARVARD UNIVERSITY

Timothy Leary

RESEARCHER, PROFESSOR, HARVARD UNIVERSITY

Perhaps one of the most famous and legendary figures in the psychedelics world and the counterculture of the 1960s, Timothy Leary was a Harvard professor, researcher, author, and strong advocate for psychedelic drug use. He founded and led the Harvard Psilocybin Project in which he studied the therapeutic effects of psilocybin and LSD. Throughout his life, he publicly spoke about the benefits of psychedelics, popularizing the phrase, “turn on, tune in, drop out.” There is no doubt that Timothy Leary’s work has had a profound and lasting effect on the psychedelic field as we know it.

White X
headshot-Vincent-Moon
Vincent Moon INDEPENDENT FILMMAKER, ARTIST, CO-FOUNDER, COLLECTION PETITES PLANÈTES

Vincent Moon

INDEPENDENT FILMMAKER, ARTIST, CO-FOUNDER, COLLECTION PETITES PLANÈTES

Vincent Moon is a filmmaker, artist, and photographer who, together with the artist, Priscilla Telmon, created the independent production company, Collection Petites Planètes. His work has included documenting religious rituals, sacred music, shamanic rituals, and collaborating on projects that explore trance and altered states of consciousness. He has given talks on psychedelics around the world and has given art performances at psychedelics conferences, such as the Interdisciplinary Conference on Psychedelic Research.

White X
headshot-Zach-Leary
Zach Leary PODCAST HOST, THE MAPS PODCAST

Zach Leary

PODCAST HOST, THE MAPS PODCAST

Timothy Leary’s son, Zach Leary, is a yogi, writer, podcaster, wellness facilitator, guided session therapist, author, and psychedelic advocate who has learned extensively from Ram Dass. He works one-on-one with people to help them heal through the use of psychedelics, and he has also taught on a variety of topics, including the history of psychedelics, safe use, harm reduction, and how to be an effective practitioner. Leary is currently the host of the MAPS podcast, which covers all things psychedelics. He also facilitates psilocybin retreats in Jamaica.

White X

Policy / Advocacy

headshot Adriana Kertzer
Adriana Kertzer FOUNDER, PLANT MEDICINE LAW GROUP

Adriana Kertzer

FOUNDER, PLANT MEDICINE LAW GROUP

Adriana Kertzer is the founder of Plant Medicine Law Group, a cannabis and psychedelics law firm committed to increasing legal and equitable access to psychedelics and medicinal plants by helping businesses become leaders in the space. She is also a member of the Psychedelic Bar Association and on the board of Doctors for Cannabis Regulation. Kertzer’s commitment to psychedelics also expands to faith—she leads Faith+Psychedelics, a multi-religion community made up of people interested in using psychedelics to explore their religions.

White X
headshot Allison Hoots
Allison Hoots ATTORNEY, PLANT MEDICINE LAW GROUP

Allison Hoots

ATTORNEY, PLANT MEDICINE LAW GROUP

Allison Hoots is an attorney at Plant Medicine Law Group, a psychedelics and cannabis firm. She has significant experience advising churches on compliance related to the religious use of psychedelics and the right to these sacraments. In addition to founding Hoots Law Practice in 2019, she’s also the President and serving on the Board of Directors of Sacred Plant Alliance, an organization of spiritual practitioners devoted to the use of psychedelic sacraments within religious ceremonies.

White X
headshot Benjamin De Loenen
Benjamin De Loenen FOUNDER AND EXECUTIVE DIRECTOR, ICEERS

Benjamin De Loenen

FOUNDER AND EXECUTIVE DIRECTOR, ICEERS

Benjamin De Loenen directed and edited the documentary, Ibogaine-Rite of Passage, in 2004, which was about ibogaine (a dissociative psychedelic) as a promising treatment for addiction. Later, he became a public speaker and advocate for iboga, the psychedelic plant ibogaine is derived from. In 2009, De Loenen founded the International Center for Ethnobotanical Education, Research & Service (ICEERS) in the Netherlands. ICEERS, a nonprofit organization, conducts scientific research on cannabis, iboga, and ayahuasca and offers education, harm reduction services, legal support, and more.

White X
headshot Bia Labate
Bia Labate, Ph.D. EXECUTIVE DIRECTOR, CHACRUNA INSTITUTE FOR PSYCHEDELIC PLANT MEDICINES

Bia Labate, Ph.D.

EXECUTIVE DIRECTOR, CHACRUNA INSTITUTE FOR PSYCHEDELIC PLANT MEDICINES

Dr. Bia Labate, who has a Ph.D. in Anthropology, is extremely invested in the fields of religion and ritual, drug policy, and psychoactive substances, including psychedelics. She is the Executive Director of the Chacruna Institute for Psychedelic Plant Medicines and the Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS). Dr. Labate has also written, co-authored, and co-edited seventeen books, including Psychedelic Justice: Toward a Diverse and Equitable Psychedelic Culture, Ayahuasca Healing and Science, Plant Medicines, Healing, and Psychedelic Science, and Peyote: History, Traditions, Politics, and Conservation. Dr. Labate is also a co-founder of the Interdisciplinary Group for Psychoactive Studies.

White X
headshot Carl Hart
Carl Hart, Ph.D. CHAIR OF PSYCHOLOGY DEPARTMENT, COLUMBIA UNIVERSITY

Carl Hart, Ph.D.

CHAIR OF PSYCHOLOGY DEPARTMENT, COLUMBIA UNIVERSITY

Dr. Carl Hart is a neuropsychopharmacologist, activist, educator, and author. He serves as Chair of Columbia University’s Department of Psychology. His research focuses on the neurophysical and behavioral effects of psychedelics in human beings. He has discussed his work on The Joe Rogan Experience, The O’Reilly Factor, and Democracy Now! He wrote the book, Drug Use for Grown-Ups, which reframes how we view autonomous adults who use psychoactive substances, challenges harmful stereotypes about people who use drugs, and advocates for the right to use substances.

White X
headshot Deidra Somerville
Deidra Somerville, Ph.D., MSW EXECUTIVE DIRECTOR, ALCHEMY COMMUNITY THERAPY CENTER

Deidra Somerville, Ph.D., MSW

EXECUTIVE DIRECTOR, ALCHEMY COMMUNITY THERAPY CENTER

Dr. Deidra Somerville received her Ph.D. in Community Psychology from National Louis University and is a healer, scholar, activist, and Executive Director of Alchemy Community Therapy Center, a nonprofit which provides affordable psychedelic-assisted treatment to marginalized people like BIPOC and LGBTQ+ communities and psychedelics training to diverse treatment providers. Her work has greatly increased access to life-changing psychedelic therapy that may have otherwise been inaccessible to those who need it.

White X
headshot Dustin Robinson
Dustin Robinson FOUNDER, MR. PSYCHEDELIC LAW

Dustin Robinson

FOUNDER, MR. PSYCHEDELIC LAW

Dustin Robinson, a CPA and attorney, founded the nonprofit, Mr. Psychedelic Law, whose mission is to use research to inspire psychedelic legal reform in Florida. He also founded Iter Investments, an investment fund for psychedelics, which is backed by scientists, doctors, lawyers, investors, and more, and supports companies in the psychedelic space to improve mental health and well-being.

White X
headshot Ethan Nadelmann
Ethan Nadelmann, Ph.D. FOUNDER, DRUG POLICY ALLIANCE

Ethan Nadelmann, Ph.D.

FOUNDER, DRUG POLICY ALLIANCE

Ethan Nadelmann, who received his Ph.D. from Harvard, is known as one of the leading advocates for drug policy reform in the United States and beyond. He founded the Drug Policy Alliance in 2000, a nonprofit dedicated to ending the War on Drugs and advocating for harm reduction. Nadelmann also co-founded the Open Society Institute’s International Harm Reduction Development (IHRD) program and has been on the advisory board of the Global Drug Policy Project (GDPP), where his efforts have been very impactful. In 2021, he started a podcast called Psychoactive, which focuses on drug research, drug use, and drug policy.

White X
headshot Henrik Jungaberle
Henrik Jungaberle, Dr. sc. hum. FOUNDER AND EXECUTIVE DIRECTOR, MIND FOUNDATION

Henrik Jungaberle, Dr. sc. hum.

FOUNDER AND EXECUTIVE DIRECTOR, MIND FOUNDATION

Henrik Jungaberle received his doctorate from the Medical Faculty of the University of Heidelberg; after that, he worked at the Institute of Medical Psychology, University Hospital Heidelberg, for eighteen years, where he researched psychoactive substances. He is the Founder and Executive Director of the MIND Foundation, a European nonprofit organization that engages in psychedelic research, works with policymakers, educates the public on psychedelic-assisted treatment, trains professionals, and more.

White X
headshot Ismail Ali
Ismail L. Ali, J.D. DIRECTOR OF POLICY AND ADVOCACY, MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES (MAPS)

Ismail L. Ali, J.D.

DIRECTOR OF POLICY AND ADVOCACY, MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES (MAPS)

Ismail L. Ali, who earned his J.D. at the University of California, Berkeley School of Law, is an educator, advocate, and attorney serving as the Director of Policy and Advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS). His goal in this role is to increase access to psychedelic research and treatment, as well as implement policy strategies. Prior to MAPS, he worked for the ACLU of Northern California’s Criminal Justice & Drug Policy Project. Ali is a founding board member and co-chair of the Psychedelic Bar Association and has served in leadership roles for many organizations related to drug policy, including Chacruna Institute and the Ayahuasca Defense Fund, and the Sage Institute.

White X
headshot Jack Bunce
Jack Bunce CO-FOUNDER AND COURSE DEVELOPER, HOW TO USE PSYCHEDELICS

Jack Bunce

CO-FOUNDER AND COURSE DEVELOPER, HOW TO USE PSYCHEDELICS

Along with Louis Belleau, Jack Bunce, psychedelics advocate, personal growth facilitator, and community organizer, co-founded How to Use Psychedelics, a platform designed to provide accessible information and resources to people who want to safely use psychedelics for their own growth, healing, and self-discovery. He was inspired by his personal journey with psychedelics and healing, in which psychedelics helped him overcome PTSD, OCD, and anxiety.

White X
headshot Jon Dennis
Jon Dennis, J.D. EXECUTIVE DIRECTOR, VITAL OREGON

Jon Dennis, J.D.

EXECUTIVE DIRECTOR, VITAL OREGON

Jon Dennis, who earned his J.D. from the Lewis & Clark Law School, is a consultant, psychedelic lawyer, and activist. He currently serves as the Executive Director of Vital Oregon, a new project by Psychedelics Today for psilocybin facilitator training. He is the co-host of Eyes on Oregon, the Psychedelics Today podcast, which discusses news related to Oregon’s psilocybin program. He is also a member of Chacruna’s Council for the Protection of Sacred Plants and a founding member of the Entheogenic Practitioners Council of Oregon.

White X
Joshua Kappel
Joshua Kappel Founding Partner, Vicente LLP

Joshua Kappel

Founding Partner, Vicente LLP

Joshua Kappel, a founding partner of Vicente LLP, is renowned for aiding entrepreneurs in the cannabis and psychedelic sectors, and has made significant contributions to policy development, including co-authoring Colorado’s Proposition 122, the Natural Medicine Health Act. His expertise extends to assisting a wide range of companies with corporate structuring and regulatory compliance in the ever-evolving psychedelic landscape. An active figure in the emerging therapies community, Joshua is the founder and a board member of the Microdosing Collective, a pioneering nonprofit dedicated to legalizing microdosing.

White X
headshot Kilindi Iyi
Kilindi Iyi MYCOLOGIST, TEACHER, PSYCHONAUT,

Kilindi Iyi

MYCOLOGIST, TEACHER, PSYCHONAUT,

Kilindi Iyi was a traveler, mycologist, teacher, speaker, humanitarian, psychonaut, and psychedelic pioneer who was influential in the Black Liberation Movement. He first became interested in psychedelics through his African sciences and martial arts studies due to the history of integrating fungi and psychedelics plants into martial arts practices. He became a leader in the psychedelics world, focusing on high-dose psilocybin research and its ability to lead to consciousness evolution.

White X
headshot Kwasi Adusei
Kwasi Adusei, DNP, PMHNP-BC CO-FOUNDER, THE PSYCHEDELIC SOCIETY OF WESTERN NEW YORK

Kwasi Adusei, DNP, PMHNP-BC

CO-FOUNDER, THE PSYCHEDELIC SOCIETY OF WESTERN NEW YORK

Kwasi Adusei is a community organizer, educator, and psychiatric mental health nurse practitioner at the Center for Psychedelic Therapy and Research. He also co-founded the Psychedelic Society of Western New York, where he created a harm reduction program for psychedelic use called the Sanctuary Project. He has also completed the Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-Assisted Psychotherapy for PTSD Program.

White X
headshot Louis Belleau
Louis Belleau FOUNDER AND DIRECTOR, PSYGAIA AND HOW TO USE PSYCHEDELICS

Louis Belleau

FOUNDER AND DIRECTOR, PSYGAIA AND HOW TO USE PSYCHEDELICS

Louis Belleau is a writer, psychedelics advocate, and founder and director of Psygaia and How to Use Psychedelics, both of which provide accessible education and support for the safe and therapeutic use of psychedelics. The information comes from various schools of thought, including Indigenous, Eastern, Western, ancestral, and modern. He is also currently developing Nectara, a program that provides psychedelic support services, such as finding a guide, creating meaning out of your journey, and processing and reflecting on your exploration.

White X
headshot Mark Plotkin
Mark Plotkin, Ph.D. ETHNOBOTANIST, AUTHOR, PODCASTER, PLANTS OF THE GODS

Mark Plotkin, Ph.D.

ETHNOBOTANIST, AUTHOR, PODCASTER, PLANTS OF THE GODS

Dr. Mark Plotkin is an ethnobotanist who, for the past three decades, has studied Indigenous psychedelic plant use in South and Central America. He’s the President of the Amazon Conservation Team (ACT), a nonprofit he founded with his wife, Liliana Madrigal. He wrote the book, Medicine Quest: In Search of Nature’s Healing Secrets, and also gave a TED Talk in 2014 called “What the people of the Amazon know that you don’t.” Plants of the Gods is his ongoing podcast where he discusses psychedelics, their healing potential, and their impact on religion and culture.

White X
headshot Mitchell Gomez
Mitchell Gomez, M.A. EXECUTIVE DIRECTOR, DANCESAFE

Mitchell Gomez, M.A.

EXECUTIVE DIRECTOR, DANCESAFE

Mitchell Gomez is a psychedelics advocate, educator, and activist. He currently serves as the Executive Director for DanceSafe, a harm reduction and education nonprofit based in Denver, Colorado. He is also a Harm Reduction Consultant at the Multidisciplinary Association for Psychedelic Studies (MAPS) and serves on the advisory council of PsychSems and Psymposia. As a subject matter expert on harm reduction, the war on drugs, prohibition, and compounds like MDMA, ketamine, and LSD, he has written for The Guardian, Los Angeles Times, Houston Press, SF Gate, Rolling Stone Magazine, and more.

White X
Richard Nixon Photo
Richard Nixon 37th President, The United States of America

Richard Nixon

37th President, The United States of America

Though we may not love this impact, it’s hard to deny how profound it was. Richard Nixon, who was the 37th President of the United States, is responsible for the Controlled Substances Act, which established federal U.S. drug policy and made possession of psychedelics like LSD a federal offense. He also started the War on Drugs, a global campaign focused on drug prohibition. The War on Drugs halted research into the therapeutic benefits of psychedelic-assisted therapy for several decades before it finally began again.

White X
headshot Robert Roman Haferd
Robert “Roman” Haferd, J.D. RESTORATIVE JUSTICE COORDINATOR, OFFICE OF THE ATTORNEY GENERAL OF THE DISTRICT OF COLUMBIA

Robert “Roman” Haferd, J.D.

RESTORATIVE JUSTICE COORDINATOR, OFFICE OF THE ATTORNEY GENERAL OF THE DISTRICT OF COLUMBIA

Robert “Roman” Haferd, who received his Doctor of Law from Harvard University and is the Restorative Justice Coordinator for the Office of the Attorney General of the District of Columbia, is a founding board member at the Psychedelic Bar Association. Additionally, Haferd is the Director of Community Engagement for the Plant Medicine Coalition, which promotes equitable and safe access to plant medicines and psychedelics. Thanks to Haferd’s efforts, the Decriminalize Nature DC campaign passed Initiative 81, the Entheogenic Plant and Fungus Policy Act, which made psychedelics like psilocybin and LSD the lowest priorities among Washington DC law enforcement.

White X
headshot Sam Chapman
Sam Chapman EXECUTIVE DIRECTOR, THE HEALING ADVOCACY FUND

Sam Chapman

EXECUTIVE DIRECTOR, THE HEALING ADVOCACY FUND

Sam Chapman is the executive director of the Healing Advocacy Fund, a nonprofit organization developing and providing regulated psilocybin-assisted therapy to people struggling with anxiety, depression, addiction, or end-of-life distress in Colorado and Oregon. Chapman brings over ten years of experience advocating for drug policy reforms at the national, state, and local level to his role, and in 2013, he co-wrote House Bill 3460, which was the law that legalized medical marijuana dispensaries in Oregon. He also served as a campaign manager for Oregon’s Measure 109, which legalized psilocybin therapy in the state.

White X
Spiro T. Agnew Photo
Spiro T. Agnew Former Vice President, The United States of America

Spiro T. Agnew

Former Vice President, The United States of America

Spiro T. Agnew was the Vice President of the United States under President Nixon and the second Vice President to resign. During his vice presidency, he helped Nixon establish the Controlled Substances Act and launch the War on Drugs, which targeted the counterculture and recreational use of psychedelics, making it illegal on the federal level to possess psychedelics like LSD. Like Nixon, Agnew’s impact is hard to deny.

White X
headshot Thomas Roberts
Thomas B. Roberts, Ph.D. PROFESSOR EMERITUS, NORTHERN ILLINOIS UNIVERSITY

Thomas B. Roberts, Ph.D.

PROFESSOR EMERITUS, NORTHERN ILLINOIS UNIVERSITY

Thomas B. Roberts, who is a professor emeritus at Northern Illinois University, wrote the book, Psychedelic Horizons and serves as the co-editor of Psychedelic Medicine. He is known for coining the term “Bicycle Day,” which celebrates the day Albert Hofmann biked home from the lab after taking 250 mcg of LSD. As an international speaker, he has given lectures on psychedelic science and consciousness.

White X

Business

headshot Amy Emerson
Amy Emerson CEO, MAPS PUBLIC BENEFIT CORPORATION

Amy Emerson

CEO, MAPS PUBLIC BENEFIT CORPORATION

Amy Emerson is the CEO of the MAPS Public Benefit Corporation (MAPS PBC), a clinical-stage company that is a subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) and is dedicated to creating prescription psychedelics to treat mental illness. Since 2014, she has fundraised about $150 million for the company and piloted MAPS PBC through six Phase 2 studies and two Phase 3 studies. Prior to her work at MAPS PBC, Emerson led many pharmaceuticals from Phase 1 studies to FDA approval.

White X
headshot Andrew Chadeayne
Andrew Chadeayne, Ph.D. FOUNDER AND CEO, CAAMTECH

Andrew Chadeayne, Ph.D.

FOUNDER AND CEO, CAAMTECH

Andrew Chadeayne, who received a JD from the George Washington University Law School and a Ph.D. in Chemistry from Cornell, is the founder and CEO of CaaMTech, a company committed to engineering safe and therapeutic psychedelic substances. Through his leadership at CaaMTech, Chadeayne’s team has been able to make new psychoactive compounds like novel tryptamines that have the desired therapeutic effects while minimizing side effects.

White X
headshot-Anne-Philippi
Anne Philippi FOUNDER AND CEO, THE NEW HEALTH CLUB

Anne Philippi

FOUNDER AND CEO, THE NEW HEALTH CLUB

Anne Philippi is the founder and CEO of The New Health Club, a psychedelic community, podcast, newsletter, and space for therapists, scientists, investors, and other influential people in the psychedelic space to talk about the emerging psychedelic space.

White X
headshot-Carey-Turnbull
Carey Turnbull FOUNDING DONOR AND CHAIR OF THE ADVISORY BOARD, NYU CENTER FOR PSYCHEDELIC MEDICINE

Carey Turnbull

FOUNDING DONOR AND CHAIR OF THE ADVISORY BOARD, NYU CENTER FOR PSYCHEDELIC MEDICINE

Carey Turnbull is a prominent psychedelic medicine advocate. He is the founding donor and the Chair of the Advisory Board of the NYU Center for Psychedelic Medicine, which is focused on research into the therapeutic potential of psychedelic drugs and compounds. He is also a member of the board and President of the Heffter Research Institute, a nonprofit that researches psilocybin’s potential to treat addiction and cancer-related anxiety and depression. As a founder of Freedom to Operate, he has also helped protect psychedelic medicine research.

White X
headshot-Cosmo-Feilding-Mellen
Cosmo Feilding Mellen CEO, BECKLEY PSYTECH

Cosmo Feilding Mellen

CEO, BECKLEY PSYTECH

Cosmo Feilding Mellen, CEO at Beckley Psytech, first contributed to the psychedelic space by directing several documentaries about psychedelics, counterculture, and the War on Drugs. He’s since become a drug development entrepreneur committed to uncovering the therapeutic potential of psychedelics to help people recover from various mental illnesses and trauma. In 2016, he co-founded Beckley Research & Innovations and served as Managing Director and co-founder of Beckley Canopy Therapeutics, a cannabis drug discovery company that was then acquired by Canopy Growth Corporation.

White X
headshot-David-Champion
David Champion FOUNDER AND CEO, MAYA HEALTH

David Champion

FOUNDER AND CEO, MAYA HEALTH

David Champion is the founder and CEO of Maya Health, a psychedelic tech platform that serves researchers, treatment providers, and participants. Maya Health allows these users to chart real-world evidence in order to help advance therapeutic psychedelic use. They aim to use this data to inform regulation, drug development, and clinical practices. He is also the co-founder and Director at Unlimited Sciences, a psychedelic research nonprofit.

White X
Derek Du Chesne 225x300 1
Derek Du Chesne Co-Founder, CEO, Better U

Derek Du Chesne

Co-Founder, CEO, Better U

Derek Du Chesne is the co-founder and CEO of Better U, a Las Vegas-based psychedelic therapy company. Derek helped found Better U after a life-saving and transformative experience with ketamine-assisted therapy that helped him overcome severe suicidal ideation and depression. Since then, he has worked with leaders from the Stanford Psychedelic Science Center and Depression Research Clinic to help grow and explore psychedelic medicine.

White X
headshot-Dylan-Beynon
Dylan Beynon FOUNDER AND CEO, MINDBLOOM

Dylan Beynon

FOUNDER AND CEO, MINDBLOOM

Dylan Beynon is the founder and CEO of Mindbloom, a mental health company that provides app-supported, at-home ketamine therapy. The company employs a team of remote clinicians and guides that has led over 220,000 ketamine therapy sessions to support a variety of mental health diagnoses.

White X
headshot-Floris-Wolswijk
Floris Wolswijk, M.Sc. FOUNDER, BLOSSOM

Floris Wolswijk, M.Sc.

FOUNDER, BLOSSOM

Floris Wolswijk is a psychonaut, entrepreneur, writer and the founder of Blossom, a database of up-to-date psychedelic information including: events, reports, papers, and companies. Wolswijk’s contribution to psychedelic medicine allows stakeholders in the space to access vital knowledge to help aid the transition from clinical trials and research to medical practice.

White X
headshot Ingmar Gorman
Ingmar Gorman, Ph.D. CO-FOUNDER, FLUENCE

Ingmar Gorman, Ph.D.

CO-FOUNDER, FLUENCE

Dr. Ingmar Gorman, who previously co-led an FDA-approved Phase 3 clinical trial of MDMA-assisted therapy for PTSD, is the co-founder of Fluence, a company that provides professional training, including accredited courses and certificates, in psychedelic-assisted psychotherapy, psychedelic integration, and harm reduction. Dr. Gorman is also currently conducting a Phase III FDA-approved clinical trial studying the efficacy of MDMA-assisted therapy for PTSD and a study investigating psilocybin for treatment-resistant depression.

White X
headshot Jackie von Salm
Jackie von Salm, Ph.D. CO-FOUNDER AND CSO, PSILERA BIOSCIENCE

Jackie von Salm, Ph.D.

CO-FOUNDER AND CSO, PSILERA BIOSCIENCE

Dr. Jackie von Salm, who received her Ph.D. at the University of South Florida, is a biochemist who co-founded and serves as CSO of Psilera Bioscience, a biotech research company that focuses on non-hallucinogenic psychedelic drug discovery and development. Her focus is on isolating medicinal plant compounds to treat neurological conditions.

White X
headshot-Josh-Hardman
Josh Hardman FOUNDER AND EDITOR, PSYCHEDELIC ALPHA

Josh Hardman

FOUNDER AND EDITOR, PSYCHEDELIC ALPHA

Josh Hardman is a writer, editor, and the founder of Psychedelic Alpha, a community and newsletter providing organizations and individual readers with interviews, news, research, and information related to psychedelic medicine. Users can learn everything from psychedelic patent and legalization information to drug development updates. Hardman’s community has the potential to empower countless medical professionals, providers, patients, researchers, and psychedelic-curious individuals.

White X
headshot-JR-Rahn
JR Rahn CO-FOUNDER, MINDMED

JR Rahn

CO-FOUNDER, MINDMED

After spending two years investing in psychedelic research, JR Rahn co-founded and (previously) served as CEO of MindMed, a psychedelic biotech company engineering psychedelic compounds and therapies to treat mental health disorders and substance use disorders.

White X
headshot-Lucia-Huang
Lucia Huang, MBA CO-FOUNDER AND CEO, OSMIND

Lucia Huang, MBA

CO-FOUNDER AND CEO, OSMIND

Lucia Huang, who has been named one of Forbes 30 Under 30 for her healthcare innovations, is the co-founder and CEO of Osmind. Osmind is a Public Benefit Corporation and tech platform for breakthrough mental health treatments like ketamine, psilocybin, and MDMA therapy. Previously, she was the Director of Operations and Finance at Verge Genomics, a biotech and drug discovery company.

White X
headshot-Marik-Hazan
Marik Hazan, MBA FOUNDING PARTNER, TABULA RASA VENTURES

Marik Hazan, MBA

FOUNDING PARTNER, TABULA RASA VENTURES

Marik Hazan is an investor, entrepreneur, psychedelic advocate, and engineer who runs an international and renowned psychedelics conference, Psyched. As the founding partner of Tabula Rasa Ventures, a venture capitalist firm for startup psychedelic companies, he has helped support drug development and medicinal psychedelics research. Hazan is also the CEO of Energia Holdings Inc., which is revolutionizing healthcare by prioritizing the underfunded areas of the industry, including psychedelics.

White X
headshot Mendel Kaelen
Mendel Kaelen, Ph.D. FOUNDER AND CEO, WAVEPATHS

Mendel Kaelen, Ph.D.

FOUNDER AND CEO, WAVEPATHS

Mendel Kaelen is a neuroscientist, psychedelics researcher, and entrepreneur who founded Wavepaths, focused on a custom-built app and tool which facilitates personalized music experiences for deep listening and psychedelic therapy. Kaelen has done considerable research into the neurological effects of music during LSD-assisted therapy. Prior to founding Wavepaths, he was a postdoctoral neuroscientist at Imperial College London, where he studied the role of music in psychedelic-assisted treatment.

White X
headshot Molly Maloof
Molly Maloof, M.D. FOUNDER AND CEO, ADAMO BIOSCIENCE

Molly Maloof, M.D.

FOUNDER AND CEO, ADAMO BIOSCIENCE

Molly Maloof is a doctor, educator, author, speaker, medical advisor, CEO, and founder of Adamo Bioscience, a biotech company researching and developing psychedelic compounds to treat hypoactive sexual desire disorder (HSDD) for people in romantic relationships. She previously founded Adaptive, a wellness and health brand that was acquired in 2021. She also served as a lecturer at Stanford University within the Wellness Department of the School of Medicine.

White X
headshot paul f austin
Paul F. Austin FOUNDER AND CEO, THIRD WAVE

Paul F. Austin

FOUNDER AND CEO, THIRD WAVE

Paul F. Austin is a psychedelic microdosing coach, author, and entrepreneur who believes in the power of psychedelics. He is the founder and CEO of Third Wave, which educates people on how to use psychedelics for professional development and personal transformation. He is also the author of Microdosing Psychedelics: A Practical Guide to Upgrade Your Life.

White X
headshot Payton Nyquvest
Payton Nyquvest FOUNDER, CHAIR, AND CEO, NUMINUS

Payton Nyquvest

FOUNDER, CHAIR, AND CEO, NUMINUS

Payton Nyquvest, who says his life was saved by psychedelics, is the founder, chair, and CEO of Numinus, an integrated and multidisciplinary mental health company that provides people with access to safe psychedelic-assisted therapies, such as ketamine, psychedelic integration, trauma-informed psychotherapy, and more.

White X
headshot Richard Skaife
Richard Skaife FOUNDER, THE CONSCIOUS FUND

Richard Skaife

FOUNDER, THE CONSCIOUS FUND

Richard Skaife is an investor and founder of The Conscious Fund, which invests in early-stage psychedelic companies looking to improve treatment for pain, addiction, and mental illness. He is also Chair of Microdose, an educational platform for the business of psychedelics, and on the board at Hive, which offers ketamine-assisted therapy retreats in Europe.

White X
headshot Ronan Levy
Ronan Levy, J.D. CO-FOUNDER, FIELD TRIP HEALTH

Ronan Levy, J.D.

CO-FOUNDER, FIELD TRIP HEALTH

Ronan Levy is a psychedelics pioneer, visionary, and entrepreneur who co-founded Field Trip Health, a company offering medically-supervised, psychedelic-assisted treatment in various clinics throughout Europe and North America. He has since exited Field Trip Health. Levy is a partner at Grassfed Ventures, which invests in biotech and cannabis companies, and co-founded Canadian Cannabis Clinics and CanvasRx Inc.

White X
headshot Simeon Schnapper
Simeon Schnapper MANAGING PARTNER, JLS FUND

Simeon Schnapper

MANAGING PARTNER, JLS FUND

Simeon Schnapper is an investor and psychedelic advocate who serves as a managing partner at JLS Fund, a venture capitalist firm that invests in psychedelics and technology, enhancing access to plant medicine therapies. A longtime psychonaut, he studied with Jean Houston, Ph.D. and Dr. Robert E.L. Masters, who co-authored The Varieties of Psychedelic Experience: The Classic Guide to the Effects of LSD on the Human Psyche and learned from various traditional practitioners and ayahuasqueros in the Amazon.

White X
headshot Yaron Conforti
Yaron Conforti CO-FOUNDER, DIRECTOR, CEO, NOVAMIND

Yaron Conforti

CO-FOUNDER, DIRECTOR, CEO, NOVAMIND

Yaron Conforti, who has more than 20 years of venture capital investing experience, is the principal of EmmCap Corp, which has invested in psychedelic companies like IM Cannabis, Enveric Biosciences, and Abacus Health Products. He is also the co-founder, director, and CEO of Novamind, a tool that can aid in organizing and mapping out thoughts and ideas.

White X

Rising Stars

headshot Alan Davis
Alan K. Davis, Ph.D. ADJUNCT ASSISTANT PROFESSOR, DIRECTOR CENTER FOR DRUG RESEARCH, JOHNS HOPKINS PSYCHEDELIC RESEARCH UNIT

Alan K. Davis, Ph.D.

ADJUNCT ASSISTANT PROFESSOR, DIRECTOR CENTER FOR DRUG RESEARCH, JOHNS HOPKINS PSYCHEDELIC RESEARCH UNIT

Dr. Alan K. Davis received their Ph.D. in Clinical Psychology from Bowling Green and was a postdoctoral fellow at Johns Hopkins. They now serve as an Assistant Professor of Social Work at the Ohio State University and an Adjunct Assistant Professor at Johns Hopkins Psychedelic Research Unit. Dr. Davis has worked with patients with anxiety, depression, PTSD, and substance addiction, providing various types of therapy like CBT as well as psilocybin-assisted psychotherapy. Their research has focused on the therapeutic potential of psilocybin for those with depression as well as how psilocybin can improve mental functioning and health, and upcoming psychedelic research will explore the use of psychedelics in vulnerable populations such as people of color who have experienced racial trauma.

White X
headshot Alex Gearin
Alex K. Gearin, Ph.D. ANTHROPOLOGIST, UNIVERSITY OF HONG KONG

Alex K. Gearin, Ph.D.

ANTHROPOLOGIST, UNIVERSITY OF HONG KONG

Dr. Alex K. Gearin is a medical and cultural anthropologist at the University of Hong Kong researching globalization, religiosity, meditation, and psychedelics, particularly ayahuasca in Australian, Chinese, and Peruvian communities. He has published scientific articles on traditional plant medicine practices, purging and ayahuasca use, the roles of rituals, the ethics of ayahuasca tourism, spirituality, and individualism within psychedelic ritual groups, and more. Dr. Gearin is currently writing a book about the therapeutic benefits of ayahuasca in different areas of the world.

White X
headshot Andres Gomez Emilsson
Andrés Gómez Emilsson, M.A. PRESIDENT AND DIRECTOR OF RESEARCH, QUALIA RESEARCH INSTITUTE

Andrés Gómez Emilsson, M.A.

PRESIDENT AND DIRECTOR OF RESEARCH, QUALIA RESEARCH INSTITUTE

Andrés Gómez Emilsson, who has a Master’s in Psychology from Stanford, is the President and Director of Research at Qualia Research Institute (QRI), a nonprofit organization devoted to mapping out the mathematical structure of subjective experience and consciousness. The work he and his team are doing at QRI could aid in the development of psychedelic-assisted therapy, especially if “trips” and psychedelic experiences can be mathematically recorded. Emilsson is also the co-founder of the Stanford Transhumanist Association.

White X
headshot Andrew Gallimore
Andrew Gallimore, M.D. NEUROBIOLOGIST, CHEMIST, PHARMACOLOGIST, THE OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY

Andrew Gallimore, M.D.

NEUROBIOLOGIST, CHEMIST, PHARMACOLOGIST, THE OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY

Dr. Andrew Gallimore is a chemist, pharmacologist, computational neurobiologist, and writer based at the Okinawa Institute of Science and Technology. He is deeply interested in psychedelics, particularly DMT. He has given many talks and published several research papers on the effects of DMT on the brain and consciousness. Gallimore is also the author of the books, Alien Information Theory and Reality Switch Technologies, both of which discuss psychedelics and their many possibilities and uses. He has also teamed up with Dr. Rick Strassman, psychedelics pioneer, to develop a model of controlled, intravenous DMT use for extended experiences. His published works include Restructuring Consciousness – the Psychedelic State in Light of Integrated Information Theory and A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.

White X
headshot Anna Becker
Anna Becker PH.D. CANDIDATE, UNIVERSITY OF BASEL

Anna Becker

PH.D. CANDIDATE, UNIVERSITY OF BASEL

Anna Becker is currently a Ph.D. student at the University of Basel, where she studied Neuroscience and Clinical Psychology. In the past, she assisted with research into decision-making and judgment in individuals with schizophrenia. Now, she investigates the role of the 5-HT2A receptor, part of the serotonin receptor family, in LSD and psilocybin use. She’s interested in both how psychedelics work and their potential clinical uses. Dr. Becker has helped guide over 80 individual psychedelic experiences with healthy study participants.

White X
headshot Anthony Bossis
Anthony P. Bossis, Ph.D. CLINICAL ASSISTANT PROFESSOR, DEPARTMENT OF PSYCHIATRY , NYU GROSSMAN SCHOOL OF MEDICINE

Anthony P. Bossis, Ph.D.

CLINICAL ASSISTANT PROFESSOR, DEPARTMENT OF PSYCHIATRY , NYU GROSSMAN SCHOOL OF MEDICINE

Dr. Anthony P. Bossis is a clinical psychologist and assistant professor at the Department of Psychiatry at NYU Grossman School of Medicine where he has conducted FDA-approved psilocybin studies for over a decade. He’s also studied how a single psilocybin experience can significantly decrease cancer-related distress, such as hopelessness, anxiety, and depression, as well as improve well-being. Further, Dr. Bossis is on the faculty of The Center for Psychedelic Therapies and Research at the California Institute of Integral Studies and has conducted extensive research into psychedelics and palliative care.

White X
headshot Balazs Szigeti
Balazs Szigeti, Ph.D. NEUROSCIENTIST, IMPERIAL COLLEGE LONDON

Balazs Szigeti, Ph.D.

NEUROSCIENTIST, IMPERIAL COLLEGE LONDON

Dr. Balazs Szigeti, who received his Ph.D. in computational neuroscience from the University of Edinburgh, invented the methodology of “self-blinding,” which allows self-experimenters in the psychedelics space to use placebo controls without monitoring. He is currently conducting self-blinding research at Imperial College London on psychedelic microdosing and the placebo effect. In 2016, in collaboration with the Global Drug Survey, he conducted research on the effects of MDMA on the brain and revealed the harm of recreational use is often overestimated. He is also one of the architects of the OpenWorm project, an open science project that aims to simulate nervous systems.

White X
headshot Brandon Weiss
Brandon Weiss, Ph.D. CLINICAL PSYCHOLOGIST AND POSTDOCTORAL RESEARCHER, CENTRE FOR PSYCHEDELIC RESEARCH

Brandon Weiss, Ph.D.

CLINICAL PSYCHOLOGIST AND POSTDOCTORAL RESEARCHER, CENTRE FOR PSYCHEDELIC RESEARCH

Dr. Brandon Weiss is a post-doctoral research associate and clinical psychologist exploring how psychedelics can affect post-traumatic stress, health and well-being, Dr. Weiss’ research areas also include the medicinal benefits of ibogaine and ayahuasca for the special forces’ veteran population. He currently leads the self-blinding microdosing study at Imperial College London along with Balazs Szigeti and others.

White X
headshot Christopher Timmermann Slater
Christopher B. Timmermann Slater, Ph.D., B.Sc. RESEARCH ASSOCIATE, CENTRE FOR PSYCHEDELIC RESEARCH

Christopher B. Timmermann Slater, Ph.D., B.Sc.

RESEARCH ASSOCIATE, CENTRE FOR PSYCHEDELIC RESEARCH

Dr. Christopher Timmermann’s research and work focuses on the psychology, pharmacology, psychiatry, neuroscience, and the ethics of psychedelic use. Currently a Research Associate at Imperial College London at the Centre for Psychedelic Research, he previously led the very first DMT brain imaging study on consciousness and potential therapeutic uses. He is also a columnist for Psychology Today, where he writes about psychedelics.

White X
headshot Danielle Herrera
Danielle M. Herrera, M.A., LMFT, AMFT PSYCHOTHERAPIST, SAGE INTEGRATIVE HEALTH

Danielle M. Herrera, M.A., LMFT, AMFT

PSYCHOTHERAPIST, SAGE INTEGRATIVE HEALTH

Danielle M. Herrera is a psychotherapist who provides ketamine-assisted therapy, harm reduction therapy, and psychedelic integration at Sage Integrative Health and at the California Center for Change. Although she works with many types of patients, her focus is on historically marginalized people, such as people of color, LGBTQ+ patients, individuals with substance use disorder, have a history of trauma, or are undergoing end-of-life care.

White X
headshot Edward Jacobs
Edward Jacobs DPHIL STUDENT AND RESEARCH FELLOW, UNIVERSITY OF OXFORD

Edward Jacobs

DPHIL STUDENT AND RESEARCH FELLOW, UNIVERSITY OF OXFORD

Edward Jacobs, M.Sc. in Philosophy of Mind, Cognitive Neuroscience and Buddhist Studies, is currently a DPhil student and research fellow at the University of Oxford, within the NEUROSEC team at the Department of Psychiatry and the Wellcome Centre for Ethics and Humanities. His psychedelic research began in 2018 when he was a Science Officer at the Beckley Foundation, and his work has continued to contribute to ethical and scientific advancements in the cannabis and psychedelic space.

White X
headshot Ellen Wong
Ellen Wong PSYCHEDELIC FACILITATOR, DOUBLEBLIND MAGAZINE AND THE ANCESTOR PROJECT

Ellen Wong

PSYCHEDELIC FACILITATOR, DOUBLEBLIND MAGAZINE AND THE ANCESTOR PROJECT

Ellen Wong is a psychedelic advocate, breathwork and medicine journey guide, and psychedelic facilitator who co-created We Are All Daughters, a medicine healing experience and retreat, and its associated podcast, Woo Knew, which focuses on transformation, healing, and uplifting people of color. She has studied shamanic practices with the shamanic practitioner, Mimi Young, and completed a Psychedelic Sitters program. Currently, Wong is a facilitator for The Ancestor Project and DoubleBlind Magazine, both of which integrate psychedelic medicine into healing journeys.

White X
headshot Emma Eckernas
Emma Eckernäs PH.D. STUDENT IN CLINICAL PHARMACOLOGY, UNIVERSITY OF GOTHENBURG, SWEDEN

Emma Eckernäs

PH.D. STUDENT IN CLINICAL PHARMACOLOGY, UNIVERSITY OF GOTHENBURG, SWEDEN

Emma Eckernäs has an M.Sc. in Pharmacy from the University of Gothenburg and is currently a Ph.D. candidate at the University of Gothenburg in the Unit for Pharmacokinetics and Drug Metabolism. Her psychedelic research focuses on DMT and its mechanism of action, effects on the body, and how the drugs move throughout the body, all of which can help guide dosing for future research and clinical applications.

White X
headshot Friederike Holze
Friederike Holze, Ph.D. POSTDOCTORAL RESEARCHER, UNIVERSITY HOSPITAL BASEL AND UNIVERSITY OF BASEL

Friederike Holze, Ph.D.

POSTDOCTORAL RESEARCHER, UNIVERSITY HOSPITAL BASEL AND UNIVERSITY OF BASEL

Dr. Friederike Holze, who is currently a postdoctoral researcher at the University Hospital Basel, where she studies the pharmacodynamics and pharmacokinetics of psychedelics, such as LSD and MDMA. She has also assisted with research on the therapeutic use of LSD as a treatment for various anxiety disorders, which could potentially help countless people recover. Currently, she is involved in Phase II investigations of the medical potential of LSD.

White X
headshot Giuliana Furci
Giuliana Furci FOUNDER AND CEO, FUNDACIÓN FUNGI (FUNGI FOUNDATION)

Giuliana Furci

FOUNDER AND CEO, FUNDACIÓN FUNGI (FUNGI FOUNDATION)

Giuliana Furci is a mycologist and the founder and CEO of the Fundación Fungi (Fungi Foundation), a non-profit research and education group dedicated to learning more about the wonderous world of fungi. In addition to being the first NGO in the world dedicated to the protection of fungi, the foundation also explores potential new uses for fungi, makes recommendations for the conservation of fungal species, and furthers awareness and education regarding all things fungus. Furci is also a co-chair of the IUCN Fungal Conservation Committee, and co-author of several publications including Biodiversidad de Chile: Patrimonio y Desafíos.

White X
headshot Hannah Douglass
Hannah Douglass PH.D. CANDIDATE, M.SC. TRANSLATIONAL NEUROSCIENCE, CENTRE FOR PSYCHEDELIC RESEARCH

Hannah Douglass

PH.D. CANDIDATE, M.SC. TRANSLATIONAL NEUROSCIENCE, CENTRE FOR PSYCHEDELIC RESEARCH

Hannah Douglass, who is the recipient of the President’s Ph.D. Scholarship to research the efficacy of psilocybin as a treatment for anorexia, is currently a Ph.D. student at Imperial College London’s Centre for Psychedelic Research. She is focused on studying how psychedelics can help improve interoceptive awareness, and cognitive flexibility.

White X
headshot Isabel Wiessner
Isabel Wiessner PH.D. CANDIDATE, POSTDOCTORAL FELLOW, EDERAL UNIVERSITY OF RIO GRANDE DO NORTE, NATAL, BRAZIL

Isabel Wiessner

PH.D. CANDIDATE, POSTDOCTORAL FELLOW, EDERAL UNIVERSITY OF RIO GRANDE DO NORTE, NATAL, BRAZIL

Isabel Wießner received her Ph.D. from the University of Campinas, São Paulo, Brazil. During her time in her doctoral program, she facilitated Brazil’s very first double-blind placebo-controlled human research on LSD and how it affects creativity, thinking, and consciousness. The study also investigated how LSD impacts therapeutic and psychotic experiences. Now, Wiessner works as a postdoctoral fellow at the Federal University of Rio Grande do Norte, Natal, Brazil, where she researches how DMT and ayahuasca affect brain activity.

White X
headshot Jeeshan Chowdhury
Jeeshan Chowdhury, M.D., Ph.D. FOUNDER AND CEO, JOURNEY COLAB

Jeeshan Chowdhury, M.D., Ph.D.

FOUNDER AND CEO, JOURNEY COLAB

Dr. Jeeshan Chowdhury received his M.D. at University of Alberta and his doctorate at Oxford as a Rhodes Scholar. Trained in psychedelic-assisted therapy, he is the founder and CEO of Journey Colab, a biopharmaceutical company committed to engineering psychedelic medicines, including mescaline, to treat addiction and mental health conditions. Journey doesn’t just develop drugs, it also creates a comprehensive model of addiction care that combines community support, psychotherapy, and psychedelic-assisted therapy.

White X
headshot Jordan Sloshower
Jordan Sloshower, M.D., M.Sc. CLINICAL INSTRUCTOR OF PSYCHIATRY, YALE UNIVERSITY

Jordan Sloshower, M.D., M.Sc.

CLINICAL INSTRUCTOR OF PSYCHIATRY, YALE UNIVERSITY

Dr. Jordan Sloshower is a psychiatrist, psychedelics researcher, and professor at Yale University, where he also received his M.D. He primarily studies the therapeutic potential of psychedelic substances and how they can be combined with psychotherapy and other treatment modalities to offer integrated and comprehensive care. At Yale, he also co-founded the Psychedelic Science Group, where he investigates psilocybin-assisted treatment.

White X
headshot Justin Strickland
Justin Strickland, Ph.D. ASSISTANT PROFESSOR, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Justin Strickland, Ph.D.

ASSISTANT PROFESSOR, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Dr. Justin Strickland is a behavioral pharmacologist and assistant professor at Johns Hopkins University School of Medicine in the Department of Ps